

Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis

Manou Huijben  | M. Tycho W.T. Lock | Vincent F. de Kemp | Laetitia M.O. de Kort | H.M.K van Breda

Department of Urology, University Medical Centre Utrecht, Utrecht, The Netherlands

Correspondence

M. Huijben, Department of Urology, University Medical Center Utrecht, Utrecht University, Room C04.236, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Email: M.Huijben@umcutrecht.nl

Abstract

Background: Male hypogonadism is a clinical and biochemical androgen insufficiency syndrome, becoming more prevalent with age. Exogenous testosterone is first-choice therapy, with several side effects, including negative feedback of the hypothalamic–pituitary–gonadal axis, resulting in suppression of intratesticular testosterone production and spermatogenesis. To preserve these testicular functions while treating male hypogonadism, clomiphene citrate is used as off-label therapy. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of clomiphene citrate therapy for men with hypogonadism.

Methods: The EMBASE, PubMed, Cochrane databases were searched in May 2021, for effectiveness studies of men with hypogonadism treated with clomiphene citrate. Both intervention and observational studies were included. The Effective Public Health Practice Project Quality Assessment Tool, a validated instrument, was used to assess methodological study quality. The primary outcome measure was the evaluation of serum hormone concentration. Secondary outcomes were symptoms of hypogonadism, metabolic and lipid profile, side effects, safety aspects.

Results: We included 19 studies, comprising four randomized controlled trials and 15 observational studies, resulting in 1642 patients. Seventeen studies were included in the meta-analysis, with a total of 1279 patients. Therapy and follow-up duration varied between one and a half and 52 months. Total testosterone increased with 2.60 (95% CI 1.82–3.38) during clomiphene citrate treatment. An increase was also seen in free testosterone, luteinizing hormone, follicle stimulating hormone, sex hormone-binding globulin and estradiol. Different symptom scoring methods were used in the included studies. The most frequently used instrument was the Androgen Deficiency in Aging Males questionnaire, whose improved during treatment. Reported side effects were only prevalent in less than 10% of the study populations and no serious adverse events were reported.

Conclusion: Clomiphene citrate is an effective therapy for improving both biochemical as well as clinical symptoms of males suffering from hypogonadism. Clomiphene citrate has few reported side effects and good safety aspects.

KEYWORDS

clomiphene citrate, male hypogonadism, testosterone deficiency

1 | BACKGROUND

Hypogonadism is a common medical condition among men.^{1,2} Hypogonadism is a clinical and biochemical testosterone insufficiency syndrome, affecting various organ functions and quality of life, according to the European Association of Urology.^{3,4} Common symptoms of hypogonadism are erectile dysfunction, reduced sexual activity and desire, mood changes, and loss of muscle strength.^{5,6} The prevalence for symptomatic hypogonadism at age 40–79 years, varies between 2.1% and 5.7%^{2,6} and increases with age and presence of obesity, cardiovascular disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM) type 2, human immunodeficiency virus (HIV), chronic kidney disease, malignancies, and metabolic syndrome.⁷

Causes of hypogonadism can be classified based on disruptions in various levels of the hypothalamic–pituitary–gonadal (HPG) axis. Primary hypogonadism is the most frequent cause of hypogonadism, resulting in low serum testosterone concentration and high serum gonadotropin concentration.³ Primary hypogonadism results from direct testicular failure; the most common reasons are Klinefelter syndrome and testicular tumors.^{8,9} On the contrary, in secondary hypogonadism the testis are inadequately stimulated by gonadotropins, resulting in hypogonadism, usually with reduced or inappropriately normal serum concentration of gonadotropins.³ Reasons for secondary hypogonadism are, for example, hyperprolactinemia, Kallmann's syndrome, and obesity.^{3,10,11} Adult-onset hypogonadism or late-onset hypogonadism, is a symptomatic testosterone deficiency in middle-aged and older men, with normal HPG-axis function.^{6,12}

Testosterone therapy (TTh) is the first-choice treatment for men with hypogonadism.¹³ The goal of this treatment aims to increase serum testosterone and restore androgen-dependent functions, for example, muscle mass and strength, sexual functions, bone density, and general well-being.^{4,14} However, TTh has some notable side effects. Subfertility is one of the most crucial side effects of TTh, especially for men with an active or possible future child wish, because endogenous testosterone is reduced by negative feedback.¹⁵ Other side effects are, for example, increase in prostate volume, increase in prostate specific antigen (PSA), elevated hematocrit (Ht), and serum estrogen concentration and serum lipid alterations.^{15–17}

Preserving fertility and costs are important reasons to not prescribe TTh for men with hypogonadism. Other medications used are human chorionic gonadotropin (hCG), aromatase inhibitors, and selective estrogen/androgen receptor modulators (SERMS and SARMS).^{18–20} Clomiphene citrate (CC) is a SERM occupying estrogen receptors in the hypothalamus and pituitary leading to gonadotropin release,

which leads to increased testicular stimulation and testosterone production.²¹ CC is used from 1960 for ovulation induction in women. It has been used off-label for men because the US Food And Drug Administration (FDA) did not approve the medicine, because of unclear effectiveness.^{22,23}

Several studies and reviews are published about the effects of CC on subfertility. Few of these studies specifically examined the effect of CC in men with hypogonadism.^{24–26} The purpose of this study was to determine if CC is an effective and safe therapy for men with hypogonadism. For this purpose, we conducted a systematic review and meta-analysis to provide oversight of the current literature in the effectiveness and safety of CC therapy for men with hypogonadism.

2 | METHODS

This systematic review and meta-analysis adhered to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).²⁷ PRISMA aims to improve the reporting of systematic reviews for randomized controlled trials (RCTs) and observational studies. This study was registered in PROSPERO under registration number CRD42021246588.

2.1 | Search strategy

A systematic search was performed using the electronic databases of EMBASE, PubMed, Cochrane in May 2021. The search strings for each database are provided in Appendix 1 (supplementary files). Search terms covered all the research on the intended population (hypogonadism) combined with the intervention (CC). On purpose, search terms for outcomes were not used, to research all possible results. Additionally, reference lists of included articles and relevant reviews were hand searched for relevant additional studies.

2.2 | Eligibility criteria and study selection

Both intervention and observational studies written in English or Dutch, on the effectiveness of CC in men with hypogonadism ≥ 18 years, were included. Outcomes had to contain at least hormonal assessment and preferably evaluation of symptoms of hypogonadism during treatment with CC. Treatment with enclomiphene,

zulomiphene, or CC combined with another medicine, were excluded. Specific disorder populations, such as chronic diseases (HIV, cancer, osteoporosis, severe kidney/liver disease, depression, hemochromatosis, acromegaly, polycythemia, Alzheimer, eating disorder, sickle cell disease, and retardation), genetic disorders (e.g., Klinefelter, Prader-Willi, Kallman, and Bardet-Biedl) were excluded. Case series $n < 5$, letters to the editor, pilot studies, reviews, comments, and animal studies were excluded. No restrictions were imposed on the year of publication, the dosage of therapy and duration of intervention. Two reviewers (H.v.B. and M.H.) independently performed study selection according to the predefined eligibility criteria. Differences in judgement were resolved by discussion. The selection was divided into three phases. First, studies were selected by title and duplications were removed. Second, abstract screening was performed. Third, articles were screened full-text for eligibility. Thereafter, the resultant articles were included.

2.3 | Data extraction and methodological quality assessment

Data were individually collected by two reviewers (H.v.B. and M.H.) for the following data: authors, year of publication, study design, type of study, single/multi-center, number of patients, presence of subgroup, therapy dosage, follow-up duration, presence of subfertility, mean age, and comorbidities. The primary outcome was hormonal assessment before and during treatment. Secondary outcomes were: symptoms of hypogonadism, metabolic and lipid profile, side effects, and safety aspects. Missing values of primary or secondary outcomes were reported as "not available" in tables. Study quality assessment was conducted of all included studies independently by two reviewers (HvB and MH) using the Effective Public Health Practice Project Quality Assessment Tool (EPHPP).²⁸ This instrument has been described as suitable to be used in systematic reviews of effectiveness and has been demonstrated to have content and construct validity.²⁸⁻³⁰ Moreover, this tool can evaluate several study designs (e.g., RCTs, before and after studies, observational studies), with an inter-assessor coefficient of 0.77 (95% CI, 0.51-0.90).³¹ The inter-assessor coefficient of 0.77 is considered an excellent consensus.³²

2.4 | Statistical analysis

Data were reported as counts, percentages, or means with standard deviations (SD). Outcomes reported by three or more studies were pooled in a meta-analysis, Review Manager (RevMan) 5.4 was used.³³ Studies were eligible for meta-analysis if mean with SD was reported. Standard errors were converted to standard deviations.³⁴ Data reported as median with interquartile range were converted to mean with SD.³⁵ The inverse-variance weighting method was used to calculate the pooled effects of before and during treatment outcomes, presented as mean differences or standardized mean differ-

ences with confidence intervals (CI).³⁴ The standardized mean difference was used when studies use different units for their outcomes, for example, nmol/L or ng/dL for TT.³⁴ Heterogeneity across studies was assessed by inspecting the forest plots and by statistical analysis using the χ^2 test and I^2 statistic. The I^2 value is the most important quantitative assessment, with interpretation as follows: 0%-40% might not be important, 30%-60% may represent moderate heterogeneity, 50%-90% may represent substantial heterogeneity, and 75%-100% may represent considerable heterogeneity.³⁴ Sensitivity analyses were performed after the primary analyses. In the sensitivity analyses for study design, only RCTs were included. In the sensitivity analyses for methodological quality, only studies with strong quality were included.

3 | RESULTS

3.1 | Study selection

The systematic search yielded a total of 569 studies (Figure 1). After removing duplicates and articles based on title, 415 studies remained. Of these studies, 383 were excluded based on abstract or on the basis of the predetermined exclusion criteria, yielding 32 studies. During screening for eligibility, full-text was assessed, leading to the exclusion of another 13 studies. In 9 out these 13 studies, full-text was not available, another three studies were excluded based on methods used, and one was excluded based on the outcome. One study exclusion was because therapy dosage was not described,³⁶ and the study population seemed to interfere with the included study of Ramasamy et al. (2014).³⁷ A second study was excluded because this study was a 10-day clomiphene challenge test.³⁸ The third study was excluded because patients were included based on men with subfertility.³⁹ The last excluded study did not clearly describe serum testosterone and symptoms.⁴⁰ In the end, 19 studies were included in the systematic review.^{37,41-58} Seventeen of these studies were included in the meta-analysis.^{37,41-46,48,50-57} Two studies were not included in meta-analysis because no standard deviations nor interquartile range were available.^{47,49}

3.2 | Study characteristics

A total of four RCTs and 15 observational cohort studies, of which 11 were retrospective, and four were prospective (Table 1). See Appendix 2 (supplementary files) for an extended oversight of study characteristics. After contact with the authors it was confirmed that there was little overlap in the study populations of Patel et al. (2015) and Keihani et al. (2020), and between Katz et al. (2012), Moskovic et al. (2012), and Mazolla et al. (2014).^{41,43-45,57} Despite the overlap between these studies, therapy duration and outcomes differed between these studies. In the 19 included studies, 1642 patients were treated with CC. Seventeen studies, containing 1279 patients treated with CC, reported mean with SD and were included in the meta-analysis. Two out of these 17 studies presented outcomes in subgroups based on age. For the meta-analysis, the subgroup with the

TABLE 1 Study- and patient characteristics and quality assessment with the global EPHPP

First author, year	Study type	n of CC and other subgroups	Dosage of therapy	Mean FU in months (SD)	Mean age in years (SD)	Global EPHPP rating
Keihani (2020)	Cohort	CC = 332	50 mg/2 days (50%), 25 mg/2 days (27%), 50 mg/day (18%) and 25 mg/day (5%)	Median 1.4 (IQR: 0.9 - 2.1)	36.2 (8.2)	Weak
Krzaste (2019)	Cohort	CC = 400	25 mg/day with titration to 50 mg/day*	≤3 years = 12.8 (9.52)	≤3 years FU = 38.5 (10.6)	Weak
				>3 years = 52.0 (10.5)	>3 years FU = 38.9 (10.4)	
Habous (2018)	RCT	CC = 90	CC = 50 mg/day	3.0	41.8 (10.4)	Weak
		CC + hCG = 76	CC + hCG = 50 mg + (5000IU) 2/week			
		hCG = 78	hCG = (5000IU) 2/week			
Soares (2018)	RCT	CC = 34	CC = 50 mg/day	3.0	CC = 35.5 (7.8)	Strong
		Placebo = 33	Placebo = placebo tablet/day		Placebo = 35.6 (7.8)	
Liel (2017)	Cohort	CC = 18	25-50 mg 3days/week*	1.6 (range, 1.4-1.8)	44.3 (6.3)	Weak
Tan (2017)	Cohort	CC = 10	50 mg/day	n.a. (range, 0.7-7.0)	50.3 (12.5)	Weak
Marconi (2016)	Cohort	CC = 27	50 mg/day	1.8	50.1 (range, 32.0-70.0)	Moderate
Patel (2015)	Cohort	CC = 47	50 mg/2 day* - 50 mg/day	Median 3.0 (IQR, 2.3 - 3.6)	34.5 (n.a.)	Weak
Bendre (2015)	Cohort	CC = 11	25 mg/2 day	3.0	n.a. (range, 18.0-21.0)	Weak
Helo (2015)	RCT	CC = 13	CC = 25 mg/day	3.0	35.0 (6.5)	Strong
		Anastrozole = 13	Anastrozole = 1 mg/day	3.0	33.0 (3.9)	
Mazzola (2014)	Cohort	CC = 76	25 mg /2 days (42%), 50 mg /2 days (22%), 50 mg/day (36%)	6.0	46.0 (22.0; range, 21.0-67.0)	Weak
Ramasamy (2014)	Cohort	CC = 31	CC = 25 mg/day	n.a.	CC = 40.9 (9.4)	Moderate
		T injections = 31	T injections = T cypionate 100-200 mg/week i.m.		T injections = 40.5 (9.2)	
		T gel = 31	T gel = Testim® 1% or Androgel® 1.62%, 2-4 pumps/day		T gel = 43.9 (13.7)	
		No therapy = 31			No therapy = 40.5 (10.4)	
Moskovic (2012)	Cohort	CC = 46	25 mg/2 days	n.a. (>12.0 months)	44.0 (18.0)	Weak
Katz (2012)	Cohort	CC = 86	25 mg/2 days (70%) and 50 mg/2 days (30%)	19.0 (14.0)	29.0 (3.0; range, 22.0-37.0)	Moderate
Da Ros (2012)	Cohort	CC = 125	25 mg/day	6.0	62.0 (11.2)	Weak
Taylor (2010)	Cohort	CC = 65	CC = 50 mg /2 days* to 25-100 mg/2 days	CC = 23.0 (range, 8-40)	CC = 42.0 (range, 19.0-70.0)	Moderate
		T gel = 38	T gel = 5 g 1% Androgel® or 5 g 1% Testim®*	T gel = 46.0 (range 6.0-149.0)	T gel = 57.0 (range, 30.0-78.0)	
Shabsigh (2005)	Cohort	CC = 36	25 mg/day	12.0	39.0 (7.0; range, 27.0-60.0)	Moderate
					<40 years (n = 24), mean = 35.6	
					>40 years (n = 12), mean = 46.0	
Guay (2003)	Cohort	CC = 178	(50 mg) 4/week	4.0	54.3 (n.a.)	Weak
					<55 years (n = 84), mean = 45.2	
					>55 years (n = 89), mean = 62.1	

(Continues)

TABLE 1 (Continued)

First author, year	Study type	n of CC and other subgroups	Dosage of therapy	Mean FU in months (SD)	Mean age in years (SD)	Global EPHPP rating
Guay (1995)	RCT, placebo cross-over	CC = 17	(50 mg) 3/week or placebo tablets 3/week	2.0	Median = 50.6 (range, 42.0-71.0)	Strong

<55 years (n = 8), mean = 53.0
>55 years (n = 9), mean = 66.4

Abbreviations: CC, clomiphene citrate; EPHPP, Effective Public Health Practice Project; FU, follow-up; hCG, human chorionic gonadotropin; i.m., intramuscular; IQR, interquartile range; n, number of patients; n.a., not available; RCT, randomized controlled trial; SD, standard deviation; T, testosterone; TTh, testosterone therapy.

*Titration until a normal level of testosterone (>300/350 ng/dL) was achieved.

largest sample size was chosen in those two studies.^{44,51} Mean therapy duration of CC and follow-up differed between one and a half and 52 months. The mean age of patients treated with CC was between 29 and 62 years. One study only observed young patients with obesity, with age between 19 and 21 years.⁵⁸ Dosage of CC therapy differed between 25 and 50 mg per day or 25, 50, or 100 mg every other day.

3.3 | Methodological quality assessment

According to the EPHPP tool, of the 19 included studies, 3 studies were assessed as strong quality,^{42,50,53} 5 studies as moderate quality,^{37,45,47,48,56} and 11 studies were assessed as weak quality^{41,43,44,46,49,51,52,54,55,57,58} (Table 1). Details regarding quality assessment can be found in Appendix 3 (supplementary files).






FIGURE 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. Search and screen process for studies about effectiveness of clomiphene citrate for hypogonadal males



(A)



(B)

FIGURE 2 Effect of clomiphene citrate on testosterone (A) and free testosterone (B). Forrest plot comparison of testosterone in patients before and during CC treatment. SD, standard deviation; Std, standardized; IV, inverse variance; CI, confidence interval

3.4 | Hormonal evaluation

Tables 2 and 3 provide an overview of serum hormone concentration before and during treatment. Mean (SD) total testosterone (TT) ranged at baseline between 179.0 ng/dL (72.0) and 310.3 ng/dL (96.0) and during treatment between 467.0 ng/dL (190.0) and 687.9 ng/dL (276.7).^{37,41–48,50–58} Data of TT before and during treatment for meta-analysis were available in 17 of the 17 included studies (98%, $n = 1256$ patients).^{37,41–46,48,50–58} One study reported TT in median (IQR), converted into mean (SD).⁴¹ Outcomes of mean TT were published in different units (nmol/L and ng/dL), so the meta-analysis presented TT in standardized mean difference. TT was higher during treatment with a standardized mean difference of 2.60 (95% CI, 1.82, 3.38; $p < 0.00001$; $I^2 = 98\%$) (Figure 2). In four studies, an improvement was found in TT during CC treatment compared with anastrozole, placebo, or no therapy (Table 2).^{37,42,50,53} The overall response rate, described in three studies, ranged between 62% and 81% and defined as an improvement of TT of at least 200 ng/dL over baseline and above 400–450 ng/dL.^{41,43,51} Mean (SD) free testosterone (FT) before and during treatment was reported in five studies (17%, $n = 222$).^{42,43,45,50,53} Outcomes of mean FT were published in different units (pmol/L and ng/dL), so in the meta-analysis, FT was presented in standardized mean difference. FT was higher during treatment with a standardized mean difference of 1.78 (95% CI, 0.65, 2.91; $p = 0.002$; $I^2 = 95\%$) (Figure 2).

Mean (SD) luteinizing hormone (LH) before and during treatment was reported in eight studies (24%, $n = 301$).^{42–45,50,53,54,58} LH was higher during treatment with a mean difference of 4.67 IU/L (95% CI, 3.67, 5.68; $p < 0.00001$; $I^2 = 77\%$) (Figure 3). Mean (SD) follicle stimulating hormone (FSH) before and during treatment was reported in six studies (14%, $n = 180$).^{42,44,50,53,54,58} FSH was higher during treatment with a mean difference of 4.25 IU/L (95% CI, 2.70, 5.81; $p < 0.00001$; $I^2 = 72\%$) (Figure 3). One study found during treatment a higher LH and FSH for CC compared with placebo, another study showed no difference between CC and anastrozole treatment in LH and FSH.^{53,57}

Eight studies reported mean (SD) serum estradiol concentration before and during treatment (47%, $n = 595$).^{42,43,45,48,51,53,57} Estradiol was higher during treatment with a mean difference of 17.69 pg/ml (95% CI, 12.46, 22.92; $p < 0.00001$; $I^2 = 82\%$) (Figure 4). A difference was found during treatment compared with placebo and anastrozole.

In three studies, hormonal outcomes were compared between age subgroups.^{46,48,50} In one study (1%, $n = 17$) there was a difference in during treatment TT between younger males (median 53 years) and older males (median 66 years).⁵⁰ This result was also found in another study (8%, $n = 125$) who showed a higher testosterone increase during CC therapy in younger patients (30–50 year) compared to patients above 50 years.⁴⁶ The third study (2%, $n = 36$) showed no higher TT in one of the two groups.⁴⁸

TABLE 2 Hormonal assessment testosterone and gonadotrophic hormones before and during treatment

Author (year)	n	Mean TT before (ng/dL, SD)	Mean TT during (ng/dL, SD)	Mean free T before (ng/dL, SD)	Mean free T during (ng/dL, SD)	Mean LH before (mIU/mL, SD)	Mean LH during (mIU/mL, SD)	Mean FSH before (mIU/mL, SD)	Mean FSH during (mIU/mL, SD)
Kelhani (2020)	CC = 332	Med 249.5 (IQR: 200.5-298.0)	Med 553.5 (IQR: 433.0-706.5)	n.a.	n.a.	Med 4.2 (2.8-6.2) (n = 256)	n.a.	Med 4.3 (2.7-7.3) (n = 306)	n.a.
Krzastek (2019)	CC = 400	Mean 249.4 (16.3)	Mean 561.6 (45.6)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	FU ≤ 3 years (n = 280)	217.18 (56.41) (n = 280)	579.28 (219.58) (n = 280)						
	FU > 3 years (n = 120)	218.29 (60.06) (n = 120)	524.40 (212.48) (n = 120)						
Habous (2018)	G1: CC = 90	243 (78)	548 (209)* G3	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	G2: CC + hCG = 76	226 (57)	531 (n.a.) * G3	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	G3: hCG = 78	222 (59)	460 (121)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Soares (2018)	CC = 34	225.54 (72.49) (n = 35)	687.94 (276.66) (n = 35) p < 0.001 BA	191.47 (60.08) (n = 30)	565.97 (217.93) (n = 30) ** BA/BG	4.25 (1.81) (n = 35)	9.75 (4.75) ** BA/BC (n = 35)	4.13 (2.77) (n = 35)	9.36 (5.81) ** BA/BG (n = 35)
	Placebo = 33	220.28 (69.30) (n = 36)	220.19 (48.46) (n = 36)	193.61 (67.28) (n = 31)	184.52 (41.12) b(n = 31)	5.10 (2.88) (n = 36)	5.00 (2.8) (n = 36)	4.56 (2.41) (n = 36)	4.53 (2.66) (n = 36)
Liel (2017)	CC = 18	219.0 (74.9)	556.2 (148.9)**	n.a.	n.a.	2.7 (2.1)	8.3 (3.5)**	4.2 (3.6)	8.6 (6.2) p < 0.007
Tan (2017)	CC = 10	246 (76)	548 (281) p < 0.01	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Marconi (2016)	CC = 27	244.9 (52.9) (n = 30)	654.2 (233.4) (n = 27)**	n.a.	n.a.	4.3	n.a.	5.1 (4.9)	n.a.
Patel (2015)	CC = 47	246.8 (97.6)	527.6 (221.5) (n = 23)	n.a.	n.a.	5.8 (4.8)	n.a.	9.6 (10.7)	n.a.
Bendre (2015)	CC = 11	233 (66)	581 (161) p < 0.0001	n.a.	n.a.	3.3 (1.6) (n = 10)	5.7 (1.7) p = 0.027	2.8 (1.5) (n = 10)	6.2 (3.0) p = 0.026 (Continues)

TABLE 2 (Continued)

Author (year) n	Mean TT before (ng/dL, SD)	Mean TT during (ng/dL, SD)	Mean free T before (ng/dL, SD)	Mean free T during (ng/dL, SD)	Mean LH before (mIU/mL, SD)	Mean LH during (mIU/mL, SD)	Mean FSH before (mIU/mL, SD)	Mean FSH during (mIU/mL, SD)
Hebo (2015) CC = 13	253 (17)	571 (SE 51) 3 months	8.3 (SE 0.85)	17 (SE 1.8) 3 months	3.9 (SE 0.45)	7.4 (SE 0.9) 3 months	4.2 (SE 1.7)	7.7 (SE 12.5)
Anastrozole = 13	248 (18)	408 (SE 56) p=0.04 BG	9.3 (SE 0.9)	14 (SE 2.0)	4.8 (SE 0.48)	6.7 (SE 1.0)	9.9 (SE 1.9)	14.0 (SE 2.8) p = 0.08
Mazzola (2014) CC = 76	179 (72)	467 (190)***	26 (190)	76 (54)***	5.2 (5.6)	10.8 (3.8)***	n.a.	n.a.
Ramasamy (2014) G1: CC = 31	247.0 (66.5)	503.5 (306.8)*** G4	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
G2: T injections = 31	223.4 (182.5)	1104.0 (866.5)*** G1/3/4	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
G3: T gel = 31	230.0 (151.0)	412.0 (339.0)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
G4: NT = 31	n.a.	310.0 (136.0)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Mošković (2012) CC = 46	228 (48)	1 year 612 (212) (n = 46)	n.a.	n.a.	2.0 (1.6)	8.6 (3.2)	n.a.	n.a.
		2 year 562 (201) (n = 37)					7.2 (4.0)	
		3 year 582 (227) (n = 29)***					8.2 (1.9)***	
Katz (2012) CC = 86	192 (87)	485 (165) p < 0.01	22 (16) pg/L	95 (35)***	2.6 (2.2)	6.8 (2.8)***	1.9 (1.7)	7.6 (1.9)***
Da Ros (2012) CC = 125	310.27 (95.95)	669.03 (239.68)*** BA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
G1: ≤ 50 year	329.18 (87.76)	794.59 (231.05)						
G2: 50–70 year	296.41 (85.53)	648.35 (238.13) p = 0.04 G1						
G3: > 70 year	335.30 (124.08)	624.03 (224.53) p = 0.006 G1						
Taylor (2010) G1: CC = 65	277 (range, 15–381)	573 (n.a.)	n.a.	n.a.	3.6 (0.0–11.6)	n.a.	3.3 (0.7–7.8)	n.a.
G2: T gel = 38	221 (range, 27–363) p < 0.05 BG	553 (n.a.)	n.a.	n.a.	7.5 (1.8–37.5) p < 0.05 BG	n.a.	7.5 (0.8–28.7)	n.a.
Shabsigh (2005) CC = 36	247.6 (39.8)	610.0 (178.6) p < 0.00001	n.a.	n.a.	2.3 (2.3) (n = 33)	n.a.	7.5 (6.8)	n.a.
G1: ≤ 40 year	251.4 (38.9)	579.7 (152.7)						
G2: > 40 year	242.2 (41.8)	652.4 (207.6)						
Guay (2003) CC = 178	n.a.	n.a.	9.3 (n.a.)	21.2 (n.a.)**	3.3 (n.a.)	7.7 (n.a.)**	n.a.	n.a. (Continues)

TABLE 2 (Continued)

Author (year)	n	Mean TT before (ng/dL, SD)	Mean TT during (ng/dL, SD)	Mean free T before (ng/dL, SD)	Mean free T during (ng/dL, SD)	Mean LH before (mIU/mL, SD)	Mean LH during (mIU/mL, SD)	Mean FSH before (mIU/ml, SD)	Mean FSH during (mIU/ml, SD)
Guay (1995)	CC = 17	237.6 (38.3)	527.0 (149.9) **	BA/PLB	10.0 (2.5)	17.8 (5.0) *** BA	6.4 (1.5) 2 months	10.2 (3.1) ***	3.4 (1.4) <i>p < 0.05</i> 2 months
G1: Med 53 year		263 (20)	489 (150)	10.3 (2.7)	17.9 (5.6)	n.a.	n.a.	n.a.	
G2: Med 67 year		222 (36) <i>p < 0.014</i> G1	577 (145)	9.3 (1.8)	18.8 (4.0)	n.a.	n.a.	n.a.	n.a.
Placebo = 17		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Abbreviations: BA, before after treatment; BG, between groups; CC, clomiphene citrate; FSH, follicle stimulating hormone; FU, follow-up; G, group; IQR, inter quartile range; LH, luteinizing hormone; Med, median; n, total number of patients; n.a., not available; n.s., no significance; NT, no therapy; T, testosterone; TT, total testosterone; TTh, testosterone therapy.

**p < 0.00*.

***p < 0.001*.

****p < 0.01*.

TABLE 3 Hormonal assessment—estradiol, testosterone-estradiol ratio, SHBG before and during treatment

Author (year) n		Estradiol before (pg/ml, SD)	Estradiol during (pg/ml, SD)	T/E ratio before	T/E ratio during	SHBG before (nmol/L, SD)	SHBG during (nmol/L, SD)
Keihani (2020)	CC = 332	Median 18.9 (14.2-23.1) (n = 265)	n.a.	n.a.	n.a.	n.a.	n.a.
Krzastek (2019)	CC = 400			n.a.	n.a.	n.a.	n.a.
	FU ≤ 3 years (n = 280)	24.24 (9.59)	44.10 (14.47) **				
	FU > 3 years (n = 120)	25.73 (14.06)	45.76 (19.71) p = 0.001				
Soares (2018)	CC = 34	32.48 (12.59) (n = 35)	89.44 (47.85) ** BA/BG (n = 35)	n.a.	n.a.	21.55 (7.86) (n = 35)	29.48 (9.79) (n = 35)
	Placebo = 33	33.45 (12.57) (n = 34)	35.77 (11.51) (n = 34)	n.a.	n.a.	22.26 (9.09) (n = 36)	23.14 (9.60) (n = 36)
Patel (2015)	CC = 47	20.8 (8.8) (n = 47)	32.0 (15.1) ** (n = 23)	n.a.	n.a.	26.1 (14.7)	29.5 (12.7) p = 0.06
Helo (2015)	CC = 13	27.6 (SE 0.9)	50 (SE 4.2) 3 months	9.3 (SE 2.5)	12.0 (SE 1.3)	22.0 (SE 8.3)	26 (SE 2.2)
	Anastrozole = 13	26.7 (SE 0.9)	25 (SE 0.1) ** BG	9.7 (SE 3.1)	17.0 (SE 1.5) p = 0.005	23.0 (SE 8.5)	22 (SE 2.3) p = 0.05
Mazzola (2014)	CC = 76	29 (31)	42 (20) ** BA	6.2 (n.a.)	11.2	n.a.	n.a.
Ramasamy (2014)	CC = 31	n.a.	20.0 (10.0)	n.a.	n.a.	n.a.	n.a.
	T injections = 31	n.a.	60.0 (58.0) ** BG	n.a.	n.a.	n.a.	n.a.
	T gel = 31	n.a.	20.0 (10.0)	n.a.	n.a.	n.a.	n.a.
	No therapy = 31	n.a.	20.0 (10.0)	n.a.	n.a.	n.a.	n.a.
Moskovic (2012)	CC = 46	37 (16)	1 year 48 (22) (n = 46)	n.a.	n.a.	n.a.	n.a.
			2 years 42 (13) (n = 37)				
			3 years 50 (30) (n = 29) p < 0.02				
Katz (2012)	CC = 86	26 (22)	39 (18) p < 0.05	n.a.	n.a.	30 (12)	32 (15) n.s.
Shabsigh (2005)	CC = 36	32.3 (10.9)	46.3 (16.6) p = 0.001	8.7 (3.5)	14.2 (5.1) p = 0.001 BA	n.a.	n.a.
	G1 ≤ 40 year	31.0 (12.4)	52.7 (16.6)	9.5 (4.1)	11.7 (4.4) p = 0.003 G2		
	G2 > 40 year	34.5 (8.1)	39.0 (13.9)	7.4 (1.9)	17.0 (4.5)		

Abbreviations: BA, before after treatment; BG, between groups; CC, clomiphene citrate; FU, follow-up; n, total number of patients; n.a., not available; n.s., no significance; Prl, prolactin; SE, standard error; SHBG, sex hormone-binding globulin; T, testosterone; T/E, testosterone-estradiol-ratio; TTh, testosterone therapy.

**p < 0.001.

3.5 | Symptoms of hypogonadism


Twelve studies describe symptoms by various questionnaires (49%, n = 798), the Androgen Deficiency in Aging Males (ADAM), quantitative ADAM score (qADAM), International Index of Erectile Function (IIEF-5), Erection Hardness Scale (EHS), and the number of intercourse events per month.^{37,41,42,44,45,47,50,52,53,55-57} Table 4 provides oversight of symptoms of hypogonadism before and during treatment with CC. There was an improvement in ADAM scores during CC treatment in

four studies (14%, n = 176).^{44,47,53,55} ADAM scores improved (a lower score is better), during CC treatment with a mean difference of -3.13 (95%, 4.16, 2.10; p < 0.00001; I² = 80%) (Figure 5). One of these studies (5%, n = 86) described an improvement on 5 out of 10 items on the ADAM questionnaire, during CC treatment.⁴⁵ However, an improvement of ADAM score was also found in another study's placebo group (2%, n = 34).⁵³ There was no difference between CC and anastrozole treatment on the qADAM score (1%, n = 13).⁴² There was a difference (p = 0.028) between increasing age and the decreasing response

TABLE 4 (Continued)

Author (year) n	Mean ADAM scores before 1-10 (SD)	Mean ADAM scores after 1-10 (SD)	Mean qADAM scores before 10-50	Mean qADAM scores after 10-50 (SD)	Mean IIEF-5 before n.a.	Mean IIEF-5 after n.a.	Mean EHS before (SD) n.a.	Mean EHS after (SD) n.a.	Intercourse events/month before (SD) n.a.	Intercourse events/month after (SD) n.a.
Moskovic (2012) CC = 46	7 (2)	1 year = 3 (2) n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		2 year = 5 (2.5)								
		3 year = 5.0 (3)								
		p = 0.01BA								
Katz (2012) CC = 86	5 (IQR, 2-7) Mean 4.75 (SD, 2.25)	2 (IQR, 1-4) Mean 2.25 (SD, 1.25)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Taylor (2010) CC = 65	4.9 (n.a.) p < 0.05	2.1 (n.a.) (n = 22)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
T gel = 38	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Guay (1995) Placebo = 17	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1.9 (1.4)	2.0 (1.4)
		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	2.0 (1.3)	

Abbreviations: ADAM, androgen deficiency in aging males score; BA, before after treatment; CC, clomiphene citrate; ED, erectile dysfunction; EHS, erection hardness score; IIEF, international index of erectile dysfunction; IQR = inter quartile range; n, total number of patients; n.a., not available; n.s., no significance; qADAM, quantitative ADAM score; SE, standard error; T, testosterone; TT, testosterone therapy.



(B)

FIGURE 3 Effect of clomiphene citrate on gonadotropins: luteinizing hormone (A) and follicle stimulating hormone (B). Forrest plot comparison of gonadotropins in patients before- and during CC treatment. SD, standard deviation; Std, standardized; IV, inverse variance; CI, confidence interval




FIGURE 4 Effect of clomiphene citrate on estradiol. Forrest plot comparison of estradiol in patients before and during CC treatment. SD, standard deviation; Std, standardized; IV, inverse variance; CI, confidence interval




FIGURE 5 Effect of clomiphene citrate on the Androgen Deficiency in the Aging Male (ADAM) questionnaire. Forrest plot comparison of ADAM questionnaire in patients before and during CC treatment.
SD, standard deviation; STD, standardized; IV, inverse variance; CI, confidence interval

of CC on attempts of sexual intercourse below and above 55 years of age (11%, $n = 178$).⁴⁹ A difference was found in the subjective improvement of symptoms, which increase more in younger patients (<55 years of age) (5%, $n = 86$).⁴⁶ There was a difference in sexual satisfaction, tip rigidity, nocturnal tumescence, intercourse attempts, for the younger group (median 53, range 42–61) who responded better to CC (1%, $n = 17$). In this double-blind, placebo-controlled trial patients were unable to distinguish for symptoms between CC and placebo.⁵⁰

3.6 | Lipid and metabolic profile

Four studies published BMI results before and during treatment (11%, $n = 184$).^{44,52,53,58} Only one study showed a decrease in BMI after 3 years of CC treatment.⁴⁴ There was no difference in BMI before and during treatment. Three studies reported total cholesterol before and during treatment (14%, $n = 224$).^{46,47,53} Only one study (8%, $n = 125$) found a decrease in total cholesterol during treatment with

TABLE 5 Metabolic and lipid profile before and during treatment

Author (year)	n	Mean BMI before (kg/m ² , SD)	Mean BMI during (kg/m ² , SD)	Mean HbA1c before (%), SD)	Mean HbA1c during (%), SD)	Mean total cholesterol before (mg/dL, SD)	Mean total cholesterol during (mg/dL, SD)
Keihani (2020)	CC = 332	Median 30.3 (range 24.4-35.1) (n = 317)	n.a.	n.a.	n.a.	n.a.	n.a.
Habous (2018)	CC = 90	30.9 (n.a.)	30.4 (n.a.)	n.a.	n.a.	n.a.	n.a.
	CC + hCG = 76	31.6 (n.a.)	31.0 (n.a.)	n.a.	n.a.	n.a.	n.a.
	hCG = 78	30.1 (n.a.)	29.7 (n.a.)	n.a.	n.a.	n.a.	n.a.
Soares (2018)	CC = 34	45.80 (11.51) (n = 37)	47.71 (8.97) (n = 37)	5.8 (0.8)	5.9 (0.8)	199.9 (35.6) (n = 35)	189.8 (28.9) (n = 35) n.s.
	Placebo = 33	46.28 (8.62) (n = 36)	46.28 (8.62) (n = 36)	5.7 (0.7)	5.8 (0.7)	190.5 (36.1) (n = 36)	191.0 (39.5) (n = 36) n.s.
Liel (2017)	CC = 18	29.9 (4.5; range, 18.6-37.6)	n.a.	n.a.	n.a.	n.a.	n.a.
Patel (2015)	CC = 47	30.2 (n.a.)	n.a.	n.a.	n.a.	n.a.	n.a.
Bendre (2015)	CC = 11	35.22 (4.8)	35.29 (4.63)	n.a.	n.a.	n.a.	n.a.
Helo (2015)	CC = 13	32.0 (SE 7.5)	n.a.	n.a.	n.a.	n.a.	n.a.
	Anastrozole = 13	33.0 (SE 9.8)	n.a.	n.a.	n.a.	n.a.	n.a.
Moskovic (2012)	CC = 46	32 (8)	1 year = 31 (9)	n.a.	n.a.	n.a.	n.a.
			2 years = 29 (11)				
			3 years = 28 (4) p < 0.05				
Da Ros (2012)	CC = 125	n.a.	n.a.	n.a.	n.a.	197.50 (39.03)	187.35 (37.48) p = 0.001
Taylor (2010)	CC = 65	n.a.	n.a.	n.a.	n.a.	171 (n.a.)	203 (n.a.) p = 0.4
	T gel = 38					199 (n.a.)	182 (n.a.) p = 0.19

Abbreviations: BMI, body mass index; CC, clomiphene citrate; SE, standard error; HbA1c, hemoglobin A1c; n, total number of patients; n.a., not available; n.s., no significance; T, testosterone.

CC.⁴⁶ Table 5 provides an oversight of the lipid and metabolic profile outcomes.

3.7 | Safety aspects and side effects

Table 6 provides information from four studies on hemoglobin (Hb), Ht, PSA, International Prostate Symptom Score (IPSS), blood pressure (BP), and bone density before and during treatment.^{44,47,51,53}

There was no difference found in Hb, Ht, total PSA, IPSS, and BP before and during treatment. Only one study (24%, n = 400) found one patient with an elevated Ht during CC treatment with no clinical significance.⁵¹ Bone density before and during treatment was measured in one study (2.8%, n = 46). They found an improvement in the femoral neck and lumbar spines' bone density over 1, 2, and 3 years. Bone density increased with the years; the presence of patients with osteoporosis decreased over the years.⁴⁴ Seven studies (20%, n = 332) reported no side effect of CC therapy.^{42-45,47,48,55} Four studies (36%,

n = 590) reported side effects between 4% and 11% of the population, for example, mood changes, blurred vision, breast/nipple tenderness, and fatigue.^{46,51,54,57} One study (2%, n = 34) did not find a difference between self-reported side effects (somnolence, weight gain, acne, asthenia, irritability, changes in bowel habits, anxiety, increased appetite, urethral candidiasis, headache, perception of testicle reduction, snoring, and cramps) between CC and placebo.⁵³

3.8 | Sensitivity analyses

In the sensitivity analyses on study design, four RCTs were included.^{42,50,52,53} In the analyses on methodological quality, three studies were included.^{42,50,53} The analysis for ADAM score was not possible to repeat because only one study was left for analysis. The other five analyses (TT, FT, estradiol, LH, and FSH) were repeated with the included studies. All results remained in favor of during treatment and held statistical significance.

TABLE 6 Safety aspects before and during treatment

Author (year)	n	Mean Ht before % (SD)			Mean Ht during % (SD)			Mean Hb before mmol/L	Mean Hb during mmol/L	Mean PSA before ng/ml (SD)	Mean PSA during ng/ml (SD)	Mean IPSS before 0-35 (SD)	Mean IPSS during 0-35 (SD)	Mean BP before mmHg (SD)	Mean BP during, mmHg (SD)	Normal bone density before	Normal bone density during
		Mean Ht before % (SD)	Mean Ht during % (SD)	Hb before mmol/L	Mean Ht during % (SD)	Hb during mmol/L	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Krzastek (2019)	CC = 400	Normal	1 patient with ↑ Ht	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Soares (2018)	CC = 34	43.9 (2.4)	44.9 (5.7)	n.a.	n.a.	0.6 (0.4)	0.8 (0.5)	8.4 (5.2)	8.6 (5.2)	SPB 126.5 (14.2)	SBP 127.2 (10.9)	DBP 81.9 (7.8)	DBP 82.9 (7.8)	DBP 81.9 (7.8)	DBP 82.9 (7.8)	n.a.	n.a.
	Placebo = 33	43.9 (2.6)	44.1 (2.7)	n.a.	n.a.	0.6 (0.5)	0.6 (0.4)	9.9 (6.0)	8.5 (5.8)	SBP 123.9 (13.8)	SBP 124.8 (11.2)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Moskovic (2012)	CC = 46	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	28%	1 year = 50%	2 years = 48%	3 years = 55%
Taylor (2010)	CC = 65	n.a.	n.a.	15.0	14.5	0.8 (n.a.)	1.0 (n.a.)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	T gel = 39	n.a.	n.a.	14.9	15.2	0.9 (n.a.)	1.14 (n.a.)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Abbreviations: BP, blood pressure; CC, clomiphene citrate; DBP, diastolic blood pressure; Hb, hemoglobin; Ht, hematocrit; IPSS, International Prostate Symptom Score; n, total number of patients; n.a., not available; PSA, prostate specific antigen; SBP, systolic blood pressure; T, testosterone.

4 | DISCUSSION

This systematic review and meta-analysis show that men with hypogonadism treated with CC, have an improvement of TT and symptoms of hypogonadism on the ADAM questionnaire. With an overall response rate between 62% and 81% for TT. This is, to our knowledge, the first meta-analysis of the current literature on this subject with the inclusion of both RCTs and observational cohort studies.

Besides the increase of TT, the FT, LH, FSH, and estradiol also increased. These elevations of testosterone and gonadotrophins show that CC is effective in improving endogenous testosterone secretion by stimulating the HPG-axis in men with hypogonadism. During CC treatment, serum TT achieved the reference value (15.6-20.8 nmol/L) sufficient for treating hypogonadism, according to the guidelines of the American Urology Association.⁵⁹ Different studies comparing CC with testosterone gel concluded the same. Taylor and Levine (2010) ($n = 103$), demonstrated no difference in biochemical outcome of serum TT between CC or usage of testosterone gel.⁴⁷ Ramasamy et al. (2014) ($n = 124$) supported this finding between the effect of CC and testosterone gel but found a higher increase of serum TT in patients who used testosterone injections compared to CC or testosterone gel.³⁷ They found no difference in outcomes on the ADAM questionnaire between TTh or CC therapy.³⁷ However, there are several advan-

tages of CC over TTh to mention, that is, less expensive, noninvasive, fertility sparing. Furthermore, testosterone injections cause a high-peak increase of exogenous TT with potential higher risk of more side effects.³⁷

It has yet to be established what the most effective dosage of CC therapy is and by which patient characteristics this may be influenced. In the included studies, the dosage varied between 25 and 50 mg/day and 25, 50, or 100 mg every other day. Keihani et al. (2020) based the dosage of CC on bioavailable testosterone, BMI, patient preferences, and symptom severity.⁴¹ However, there is lack of evidence for relevance of these variables. Four included studies titrated the dosage of CC based on TT level, measured after some time.^{47,51,54,57} In our opinion, the best treatment strategy for this moment is to start with the lowest dosage, 25 mg every other day and titrating the dosage based on reached serum TT concentration or symptom improvement.^{38,60}

Considering the duration of CC therapy, the total follow-up differed between the included studies from 1.5 to 52 months. Most studies described in the first month an effective biochemical response. A clomiphene challenge test supports this, where TT after 7 days of treatment reached above 400 ng/dL and after 10 days above 500 ng/dL.³⁸ An important question is whether there is a prolonged effect after discontinuing CC and CC's effectiveness on the long term. If we focus on biochemical response, three included studies ($n = 29-120$) did find

sustained responses of serum hormone concentration after 24 till 52 months of CC usage.^{44,47,51} To our knowledge, these are the longest and largest studies conducted on the long-term effectiveness of CC therapy for male hypogonadism.

Another critical question is whether TT level remains high after discontinuation of CC therapy. Guay et al. (2003) proposed that CC can be stopped without decrease of serum TT, however evidence lack, because the effect was not tested.⁴⁹ On the contrary, Patel et al. (2015) ($n = 27$) demonstrated the opposite with a trial stop of CC therapy. Of the 27 patients, 78% had decreased serum TT (<300 ng/dL) after 3 months, and all patients had reduced serum TT (<300 ng/dL) after 6 months.⁵⁶ This finding was supported in a study with five patients, after 5–7 months of discontinuation of CC: in three patients serum TT decreased but remained above 400 ng/dL, in two patients serum TT dropped to before treatment concentration.⁶¹ In another study in 12 out of 16 patients, serum TT remained normal 6 months after ending CC therapy, in four patients serum TT dropped to before treatment concentration.⁶² The biochemical response results after stopping CC therapy are contrary, with most studies reporting a decrease in TT after stopping CC therapy.

Another gap in current knowledge is what predictors are influencing the response on CC. Mazzola et al. (2014) ($n = 76$) stated that a low LH and greater testicular volume predict a better CC response.⁴³ Guay et al. (2003) ($n = 178$) described age and the presence of diabetes as predictors for the response to CC. In their study population, they found that younger patients respond 2.3 as likely to CC treatment as patients of 56 years and older. However, their success rate was defined as the percentage of successful intercourse attempts.⁴⁹ Another study expressed success rate in biochemical response, a higher increase of TT was found in the younger population against the elderly population, 100% and 32%, respectively.⁶³ Thereby, in the clomiphene challenge test of 10 days, a 60 ng/dL points higher TT was found in the study population below 50 years of age.³⁸ On the contrary, another included study ($n = 36$) found an opposite effect of a better TT response in older males. However, their cut-off value for age was remarkable lower (40 years). Three other included studies did not find any association between gonadotrophins, age, BMI, estradiol, or testicular axis on changes in testosterone.^{41,57,64}

Besides the biochemical response, the clinical response is equally important in the definition of hypogonadism.⁶⁰ Nevertheless, most included articles did not clearly described and reported symptoms of hypogonadism as most important finding, next to the biochemical response. Krzastek et al. (2019) ($n = 400$), reported in >75% of the patients subjective hypogonadal symptom improvement (FU > 3 years).⁵¹ The ADAM questionnaire (with relatively high sensitivity but low specificity) is one of the most used and validated screening instrument.^{65,66} In our meta-analysis the ADAM score improved. One of the included studies ($n = 86$) reported that there was an improvement in the items: "decreased libido," "lack of energy," "decreased life enjoyment," "sad/grumpy," and "decreased sports performance." However, 10% of the patients did not experience symptom improvement.⁴⁵ These results of symptoms of hypogonadism should be interpreted with caution. A placebo-controlled RCT ($n = 17$) from 1995 reported

that the population could not discriminate for symptom improvement when they used CC and when they were in the placebo period.⁵⁰ Another included RCT with placebo found a comparable improvement in both the CC group and placebo groups.⁵³ This could be because of the lack of gradation in the severity of symptoms.⁶⁷ However, when this RCT discriminated between items, they found an improvement in the CC group in "erection strength" and an improvement in "libido improvement" in both groups. These contradictory effects of CC on symptoms of hypogonadism bring us to the conclusion that symptoms of hypogonadism are of multifactorial origin and complex to summarize in one questionnaire. Therefore, we advocate for the development of the implementation of a new or updated questionnaire.

Conclusive evidence of the possible effects on the lipid and metabolic profile is still lacking. Few included studies did measure some of these potential effects. Results from our review show that BMI before and during treatment differed only in one out of four studies. In one included study ($n = 125$) total cholesterol decreased during treatment.⁴⁶ This effect was not found in two other included studies.^{47,53} Data is missing in several studies from a large part of the patient population. Therefore, more research is necessary to indicate whether CC influences the metabolic and lipid profile.

Some side effects have been reported in the included studies, but most studies did not report any. Most frequent side effects were: mood changes, blurred vision, breast/nipple tenderness, weight gain, headache. The incidence and type of side effects are comparable in comparison with the usage of CC in women, where clomiphene is an acknowledged therapy.⁶⁸ Elevated hematocrit, potentially leading to thrombo-embolic events, is one of the most concerning side effects for using CC. However, in the included studies, only one patient was described with elevated hematocrit.⁵¹ An earlier study with 200 patients on CC showed that prevalence of polycythemia was lower in CC therapy than TTh and did not develop a hematocrit high enough to require phlebotomy.⁶⁹ In women case reports on CC therapy, development of thrombosis was described, which was associated with ovarian hyperstimulation caused by CC.⁷⁰ Attention should be paid for a reversed effect of CC on the testicular function. This paradoxical effect was described in two patients of one included study.⁵⁷ The underlying pathology is unclear but has been reported before in case series.^{70,71} Further long-term follow-up (above 5 years) on CC has to be done, to see whether on the long-term CC is causing side effects.

There are several limitations to mention for this systematic review, meta-analysis and the included studies. First, meta-analysis results may be influenced by missed studies in our search. However, an extensive search was performed, and reference list were searched for additional studies. Second, with the limited amount of studies on this subject, most of our analyses exhibited substantial heterogeneity. The different study designs, the variation in CC dosage between studies, the different laboratory measurements of serum hormone concentration, and the unclear described inclusion and exclusion criteria of the studies are reasons for this heterogeneity. Furthermore, heterogeneity could have been caused by several included studies with no strict in- and exclusion criteria. Third, the methodological quality of

the included studies differed. With the inclusion of retrospective studies, there is a risk of confounding because of the retrospective study design and risk of detection bias with researchers' awareness of the treatment.

To our knowledge, this is the first systematic review with meta-analysis of this subject, with various strengths and a large study population. With a limited number of studies on this subject with different study designs, it was difficult to find a reliable quality assessment tool. However, one of the strengths is that we found a validated instrument, suitable for all type of study designs. Furthermore, with the inclusion of both RCTs and observational studies, the study population in our study may cause a better representation of the patient population in daily clinical practice. Another strength is that, with the sensitivity analysis for study design and study quality, the results were still consistent.

5 | CONCLUSION

Clomiphene citrate for men with hypogonadism improves both clinical symptoms and the biochemical testosterone insufficiency. Clomiphene citrate therapy has few reported side effects and good safety aspects. It is probably necessary to stay on clomiphene citrate therapy to keep the biochemical and clinical effect. In our opinion, clomiphene citrate is a potential effective and safe treatment and should be considered as a therapy in men with symptomatic hypogonadism, especially for those with an active or future child wish.

ACKNOWLEDGMENTS

Besides all contributing authors, there are no further people nor institutions to acknowledge.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

M.H., T.L., V.d.K., L.d.K., H.v.B., contributed to the design, to the analysis of the results and to the writing of the manuscript. M.H. and H.v.B. contributed to the data search and selection. See supplementary material for signed contribution forms of all authors.

DATA AVAILABILITY STATEMENT

Data on search results, study selection, data collection and quality assessment available on request.

ORCID

Manou Huijben  <https://orcid.org/0000-0001-6902-9694>

REFERENCES =

- Nieschlag E, Behre HM, Nieschlag S. *Andrology*. 3rd ed. Springer; 2010.
- Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab*. 2007;92(1):4241–4247.
- Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. Guidelines on male hypogonadism. *Eur Assoc Urol*. 2015.
- Khera M, Adaikan G, Buvat J, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). *J Sex Med*. 2016;13(12):1787–1804.
- Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. *J Clin Endocrinol Metab*. 2008;93:3870–3877.
- Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med*. 2010;63:123–135.
- Zarotsky V, Huang MY, Carman W, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. *Andrology*. 2014;2(6):819–834.
- Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab*. 2003;88(2):622–626.
- Eberhard J, Ståhl O, Cwikiel M, et al. Risk factors for post-treatment hypogonadism in testicular cancer patients. *Eur J Endocrinol*. 2008;158(4):561–570.
- Pitteloud N, Durrani S, Raivio T, Sykiotis GP. Complex genetics in idiopathic hypogonadotropic hypogonadism. *Front Horm Res*. 2010;39:142–153.
- Shimon I, Benbassat C. Male prolactinomas presenting with normal testosterone levels. *Pituitary*. 2014;17:246–250.
- Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. *Eur Urol*. 2009;55(1):121–130.
- Traish AM. Benefits and health implications of testosterone therapy in men with testosterone deficiency. *Sex Med Rev*. 2018;6(1):86–105.
- Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. *Nat Rev Endocrinol*. 2013;9:414–424.
- Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. *Sex Med*. 2015;3(3):165–173.
- Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. *Eur J Endocrinol*. 2011;165(5):675–685.
- Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease – the Framingham study: a 34-year follow-up. *Am Heart J*. 1994;127(3):674–682.
- Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. *Asian J Androl*. 2014;16(2):256–261.
- Crosnoe-Shipley LE. Treatment of hypogonadotropic male hypogonadism: case-based scenarios. *World J Nephrol*. 2015;4(2):245–253.
- Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. *Andrology*. 2014;2(6):794–808.
- Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. *Expert Opin Pharmacother*. 2014;15(9):1247–1264.
- Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. *BJU Int*. 2013;112:1188–1200.
- Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. *Expert Opin Pharmacother*. 2016;17(11):1561–1567.
- Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Costabile R. Clomiphene citrate for the treatment of hypogonadism. *Sex Med Rev*. 2019;7(2):272–276.

25. El Meliegy A, Motawi A, El Salam MAA. Systematic review of hormone replacement therapy in the infertile man. *Arab J Urol*. 2017;16:140–147.
26. Allag IS, Alexander NJ. Clomiphene citrate therapy for male infertility. *Urology*. 1979;14(5):500–503.
27. Page MJ, McKenzie JE & Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
28. Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. *Worldviews Evid Based Nurs*. 2004;1:176–184.
29. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess*. 2003;7(27):iii–173.
30. Jackson N, Waters E. Criteria for the systematic review of health promotion and public health interventions. *Health Promot Int*. 2005;20(4):367–374.
31. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the effective public health practice project quality assessment tool: methodological research. *J Eval Clin Pract*. 2012;18:12–18.
32. McDowell I. The theoretical and technical foundations of health management. 2006: 27–30.
33. Review Manager (RevMan). Version 5.4. The Cochrane Collaboration; 2020.
34. Higgins JPTGS. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0. The Cochrane Collaboration; 2011.
35. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005;5:13.
36. Dadhich P, Ramasamy R, Scovell J, Wilken N, Lipshultz L. Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men. *Indian J Urol*. 2017;33(3):236.
37. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. *J Urol*. 2014;192(3):875–879.
38. Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence. Male counterpart to hypothalamic amenorrhea? *J Urol*. 1991;38(4):317–322.
39. Delu A, Kiltz RJ, Kuznetsov VA, Trussell TL. Clomiphene citrate improved testosterone and sperm concentration in hypogonadal males. *Syst Biol Reprod Med*. 2020;66(6):364–369.
40. Zhu X, Huang H, Huang Y, Fu D. Clinical effects assessment of clomiphene on young man hypogonadism patients for adjuvant therapy. *Biomed Res*. 2018;29(1):96–98.
41. Keihani S, Wright LN, Alder NJ, et al. Baseline gonadotropin levels and testosterone response in hypogonadal men treated with clomiphene citrate. *Urology*. 2020;142:119–124.
42. Helo S, Ellen J, Mechlin C, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. *J Sex Med*. 2015;12:1761–1769.
43. Mazzola CR, Katz DJ, Loghmanieh N, Nelson CJ, Mulhall JP. Predicting biochemical response to clomiphene citrate in men with hypogonadism. *J Sex Med*. 2014;11(9):2302–2307.
44. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. *BJU Int*. 2012;110(10):1524–1528.
45. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. *BJU Int*. 2012;110(4):573–578.
46. Da Ros CT, Averbeck MA. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency - a prospective study. *Int Braz J Urol*. 2012;38(4):512–518.
47. Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. *J Sex Med*. 2010;7:269–276.
48. Shabsigh A, Kang Y, Shabsigh R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. *J Sex Med*. 2005;2(5):716–721.
49. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? *Int J Impot Res*. 2003;15(3):156–165.
50. Guay A, Heatley GJ. Effect of raising endogenous testosterone impotent. *J Clin Endocrinol Metab*. 1995;80(12):3546–3552.
51. Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. *J Urol*. 2019;202(5):1029–1035.
52. Habous M, Giona S, Tealab A, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. *BJU Int*. 2018;122(5):889–897.
53. Soares AH, Horie NC, Chiang LAP, et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. *Int J Obes*. 2018;42(5):953–963.
54. Liel Y. Clomiphene citrate in the treatment of idiopathic or functional hypogonadotropic hypogonadism in men: a case series and review of the literature. *Endocr Pract*. 2017;23(3):279–287.
55. Tan JS, Chang HC, Chung SD, Chen PH, Wu WC. Clomiphene citrate treatment outcomes in Taiwanese hypogonadal men: a single-center preliminary report. *Urol Sci*. 2017;28(1):50–52.
56. Marconi M, Souper R, Hartmann J, Alvarez M, Fuentes I, Guarda FJ. Clomiphene citrate treatment for late onset hypogonadism: rise and fall. *Int Braz J Urol*. 2016;42:1190–1194.
57. Patel DP, Brant WO, Myers JB, et al. The safety and efficacy of clomiphene citrate in hypoandrogenic and subfertile men. *Int J Impot Res*. 2015;27(6):221–224.
58. Bendre SV, Murray PJ, Basaria S. Clomiphene citrate effectively increases testosterone in obese, young, hypogonadal men. *Reprod Syst Sex Disord*. 2015;4(4).
59. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: a UA guideline. *J Urol*. 2018;200(2):423–432.
60. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. European Association of Urology (EAU) guidelines on male hypogonadism. *Journal of Reproductive Medicine and Endocrinology*. 2018.
61. Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. *J Clin Endocrinol Metab*. 1976;43:1370–1377.
62. Canessa ED, Cerda MLA. Hipogonadismo hipogonadotropo funcional hipotalámico idiopático pospuberal en el varón. *Rev Int Androl*. 2008;6:89–96.
63. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. *J Clin Endocrinol Metab*. 1987;65:1118–1126.
64. Salter CA, Zajicek A, Benfante N, Kattan M, Mulhall JP. MP58-05 a nomogram predicting testosterone response in men on clomiphene. *J Urol*. 2019;201:e854.
65. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. *Metabolism*. 2000;49(9):1239–1242.
66. Tancredi A, Reginster JY, Schleicher F, et al. Interest of the Androgen Deficiency in Aging Males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. *Eur J Endocrinol*. 2004;151:355–360.

67. Mohamed O, Freundlich RE, Dakik HK, et al. The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. *Int J Impot Res.* 2010;22:20–24.
68. Food and Drug Administration, Cder CLOMID ® (Clomiphene Citrate Tablets USP).
69. Wheeler KM, Smith RP, Kumar RA, Setia S, Costabile RA, Kavoussi PK. A comparison of secondary polycythemia in hypogonadal men treated with clomiphene citrate versus testosterone replacement: a multi-institutional study. *J Urol.* 2017;197(4):1127–1131.
70. Ribeiro RS, Abucham J. Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas. *Arq Bras Endocrinol Metabol.* 2011.
71. Pasqualotto FF, Fonseca GP, Pasqualotto EB. Azoospermia after treatment with clomiphene citrate in patients with oligospermia. *Fertil Steril.* 2008;90:2014.E11–2014.E12.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Huijben M, Lock MTWT, de Kemp VF, de Kort LMO, van Breda HMK. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. *Andrology.* 2022; 1–19. <https://doi.org/10.1111/andr.13146>